




**Supplementary Figure 1: Analysis of GEN1 activity throughout the cell cycle.** Extracts were prepared from HeLa cells expressing GEN1-FLAP after synchronization with a double thymidine block (16 h each, 8 h in between) and release. 8 h after the 2<sup>nd</sup> thymidine release, nocodazole was added to block the cells in mitosis, as indicated. Cell extracts were analyzed by western blotting for the indicated proteins. GEN1-FLAP was affinity purified from each sample using anti-FLAG M2 agarose beads. GEN1 was then eluted by 0.5 mg/mL 3xFLAG peptides in lysis buffer. The concentrations of eluted GEN1 were normalized such that roughly the same amount of GEN1 from each sample was assayed for HJ resolution activity.








**Supplementary Figure 2: Generation of *GEN1* knock out cell line.** (a) Sequence of the first 80-bp of *GEN1* exon 2 is shown. The 20-nt target sequence of the sgRNA for the plus strand of *GEN1* locus is labeled in red. The protospacer-adjacent motif (PAM) is labeled in blue. (b) Sequences (plus strand of each allele) of the *GEN1* locus of the *GEN1*<sup>-/-</sup> cells generated from Flp-In T-Rex 293 cell are shown. The dash indicates base deletion and red indicates base insertion. (c) Sequence chromatograms of the PCR products of the parental Flp-In T-Rex 293 cells (left panel) and the *GEN1*<sup>-/-</sup> cells (right panel), respectively. (d) Western blotting analysis of the parental Flp-In T-Rex 293 cells and the *GEN1*<sup>-/-</sup> cells.






**Supplementary Figure 3: Cellular expression of GEN1<sup>nuc</sup> does not confer DNA damage sensitivity.** (a) Flp-In T-REx 293 cells, and those expressing GEN1<sup>WT</sup> or GEN1<sup>nuc</sup>, with or without tetracyclin (Tet) induction (48 h), were grown and extracts prepared for analysis by western blotting. GEN1-FLAG was affinity-purified from each sample and assayed for HJ resolution activity. (b) Clonogenic cell survival assays with Flp-In T-REx 293 cells following expression of GEN1<sup>WT</sup> or GEN1<sup>nuc</sup> ( $\pm$ Tet) and treatment with the indicated concentrations of hydroxyurea (HU), cisplatin (Cis-Pt) or camptothecin (CPT). The data represent the mean  $\pm$  s.d. of at least three independent experiments. (c) Cells expressing GEN1<sup>nuc</sup> were incubated with or without Tet for 48 h, prior to treatment with the indicated concentrations of HU, Cis-Pt or CPT for 24 h. Extracts were prepared and analyzed by western blotting for the indicated proteins.



**Supplementary Figure 4: Western blot and SCE analysis of cells with or without expression of GEN1 proteins.** (a) Flp-In T-REx 293 cells, and those expressing GEN1<sup>WT</sup> or GEN1<sup>nuc</sup>, were treated with or without Cis-Pt (2 μM) for 1 h. The cells were then released into fresh medium for 48 h. Extracts were then prepared and analyzed by western blotting for the indicated proteins. (b) Flp-In T-REx 293 cells (-Tet) were treated with or without Cis-Pt (2 μM) for 1 h. SCE levels were quantified. Each data point represents a single metaphase. 55 metaphase cells (>2500 chromosomes) were counted per condition. Black bars represent the mean number of SCEs per 100 chromosomes per spread. *P* values were determined using a two-tailed t test. (c) Flp-In T-REx 293 cells were treated with the indicated siRNAs, and extracts were prepared and analyzed by western blotting for the indicated proteins. (d) Flp-In T-REx 293 cells expressing GEN1<sup>WT</sup> or GEN1<sup>nuc</sup> (±Tet) were treated with the indicated siRNAs, and extracts were prepared and analyzed by western blotting for the indicated proteins.



**Supplementary Figure 5: Uncropped western blots of data shown in Figures 1 and 2.**



**Supplementary Figure 5 (continued): Uncropped western blots of data shown in Figures 3 and 5.**